Oncotelic Therapeutics, Inc. (OTLC)
Oxford Ledge is still expanding full research coverage of OTLC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Oncotelic develops cancer and disease treatments through subsidiaries and a joint venture, focusing on FDA-designated rare pediatric indications.
SEC filings
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Financial statements and exhibits 2026-06-29
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Entry into material agreement; Completion of acquisition or disposition; 3.02; Financial statements and exhibits 2026-05-05
- 8-K Other material event; Financial statements and exhibits 2026-04-16
- 10-K Annual financial report with audited statements 2026-04-15
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for OTLC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open OTLC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.